Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. - Wikidata - awgldk - TriplyDB

Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease.

Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease.

http://www.wikidata.org/entity/Q37100862

about

Heart failure in chemotherapy-related cardiomyopathy: Can exercise make a difference?Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol Exercise Prevention of Cardiovascular Disease in Breast Cancer Survivors Multimodality Imaging in Cardiooncology Understanding cardiovascular injury after treatment for cancer: an overview of current uses and future directions of cardiovascular magnetic resonance Noninvasive imaging of cardiovascular injury related to the treatment of cancer Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.Cardiac complications of chemotherapy: role of imaging.Anthracyclines induce early changes in left ventricular systolic and diastolic function: A single centre study.Concomitant low-dose doxorubicin treatment and exercise Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted cardiovascular magnetic r An update on cardio-oncology.Mechanism of decreased sensitivity of dobutamine associated left ventricular wall motion analyses for appreciating inducible ischemia in older adults.Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function Utility of 3-dimensional echocardiography, global longitudinal strain, and exercise stress echocardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy.Pattern of cardiac surveillance among patients with lymphoma receiving anthracycline-based chemotherapy.Cardiac Magnetic Resonance Imaging in Oncology.Ventricular-Arterial Coupling in Breast Cancer Patients After Treatment With Anthracycline-Containing Adjuvant Chemotherapy Noninvasive Imaging of Flow and Vascular Function in Disease of the Aorta.Cardiotoxicity of anthracycline therapy: current perspectives Cardiovascular disease among breast cancer survivors: the call for a clinical vascular health toolbox.Imaging methods for detection of chemotherapy-associated cardiotoxicity and dysfunction.Chemotherapy-related cardiomyopathy: a neglected aspect of cancer survivorship.Cardiotoxicity due to chemotherapy: role of cardiac imaging.Anthracycline-Induced Cardiomyopathy in Adults.Strategies for early detection of cardiotoxicities from anticancer therapy in adults: evolving imaging techniques and emerging serum biomarkers.Current and emerging modalities for detection of cardiotoxicity in cardio-oncology.Cardiac Imaging: Multimodality Advances and Surveillance Strategies in Detection of Cardiotoxicity.Cardio-oncology: Gaps in Knowledge, Goals, Advances, and Educational Efforts.Concepts in cardio-oncology: definitions, mechanisms, diagnosis and treatment strategies of cancer therapy-induced cardiotoxicity.Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy, for the prediction of subsequent cardiotoxicity.Arterial stiffness in hematologic malignancies.Cardiac MRI: a Translational Imaging Tool for Characterizing Anthracycline-Induced Myocardial Remodeling.Frequency of Left Ventricular End-Diastolic Volume-Mediated Declines in Ejection Fraction in Patients Receiving Potentially Cardiotoxic Cancer Treatment.Echocardiography and Alternative Cardiac Imaging Strategies for Long-Term Cardiotoxicity Surveillance of Cancer Survivors Treated with Chemotherapy and/or Radiation Exposure.Altered Blood Flow Response to Small Muscle Mass Exercise in Cancer Survivors Treated With Adjuvant Therapy Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy.Biomarkers for monitoring chemotherapy-induced cardiotoxicity.

P2860

Q26740352-E1D542A7-A5DE-4DC9-8795-01EFB8FAB184 Q26768272-AED4DB05-B6CB-4C96-A576-AD8258083F56 Q26785410-B589C50D-3F9C-463E-B33B-99F444A8D68E Q26795452-A764D634-8EF0-4B9E-9A5A-148BE411A808 Q26859193-D0FFB967-02FE-4499-956E-FBD0EB11F8F8 Q27024715-943AE753-E8BE-4E7D-B784-200CC2556F0F Q27027354-CFC13443-F7C3-4701-8CAB-31B501B7CBC7 Q28087776-9E8A8113-B015-4683-B88F-4136D66B9D11 Q30401812-54B7DB12-6304-49FD-8B28-1A8F4CF1230D Q30415201-AC9FE108-AF26-4E4D-86B8-B65D4E5DF008 Q33562971-6EDC3E91-D1CF-4324-9794-760609CC4003 Q34201221-B18FF047-C628-46FD-BB2C-B3EB1B6CCDB0 Q34560383-9C158EA5-8E97-4EE0-9E43-B556176BBCE5 Q34650059-02F6B3A7-381D-435F-BC77-E36FCFFF3261 Q35315212-46F97D96-2B40-419E-9EA5-62A31B56E70C Q35538919-1BB55CFA-548D-4D3F-9225-B7FD2E3C7F9A Q35905883-BD38D9E3-C231-4402-A686-463CD876353E Q36163330-D04C33AE-349A-4AF8-AFFB-4201B83295DC Q36356100-CD59E45C-89C1-432A-B70F-2AD1192465C1 Q36558438-33B69129-6D4D-4981-9FB2-43B56B788F8E Q36676994-0FEAF00B-2395-4617-87DD-1F728C5A2D17 Q36845348-DBDBFFDC-90DA-48E0-9085-104B1DAC9851 Q38163389-C0E8D51A-D85F-45A9-825A-5D6C7DD4DD59 Q38197733-6D3BD1D7-4A1E-4974-8F18-98AB1DDCE67B Q38231301-C5EDA776-CE68-40BF-A112-CC9983D65568 Q38343043-C5FE3576-32EC-40E0-96FB-C3FD9190F2C7 Q38542462-B862B6B4-4311-4DFC-8379-DF5ADC18AEB7 Q38551776-81FAF09E-F2C7-45D1-81FE-0DC979F94AB8 Q38559474-965C9F3C-6590-4879-AAF7-0196D30B745E Q38632789-1715258A-D179-4796-ABCD-7208550CCA24 Q38657849-C9D1AE26-B500-45CC-8C9F-68DA1C722238 Q38717558-601D06F8-D452-42F2-AF54-F80420F31697 Q38773470-C6E07AD9-40F7-4060-8783-724FD7E2AACC Q38829602-280E8D29-046A-4387-AEC8-5104B063B8F4 Q38862688-C6ADFD52-C914-43B3-81D7-CBF2C92591F3 Q38877675-DB1CCAC8-AFCF-4EEC-B7F9-15678ADA7279 Q38909573-BBB2AB94-78DA-47CE-B5E0-787EA99DFC43 Q38973438-FA5D8498-743B-4889-A116-13342B9047DB Q39018351-258B76D3-14B5-4381-A62A-437FE6E075D5 Q39053477-58B8F9C8-608E-4E02-83DA-416C12D6CEA0

P2860

Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease.

http://www.wikidata.org/entity/Q37100862

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Low to moderate dose anthracyc ...... inical cardiovascular disease.

@en

Low to moderate dose anthracyc ...... inical cardiovascular disease.

@nl

type

label

Low to moderate dose anthracyc ...... inical cardiovascular disease.

@en

Low to moderate dose anthracyc ...... inical cardiovascular disease.

@nl

prefLabel

Low to moderate dose anthracyc ...... inical cardiovascular disease.

@en

Low to moderate dose anthracyc ...... inical cardiovascular disease.

@nl

P1433

Q37100862-4EFE6AB3-CD6E-456D-88DB-4CC6887671CF

P1476

Q37100862-66DCF726-8CA7-455D-A8BD-E67D28219D2A

P2093

Q37100862-1809D5D4-2EC2-4AAC-9BDB-E76EC03A09CF

Q37100862-1D8C5478-07C6-4869-B722-8419B200BCE2

Q37100862-49B55FAB-AB81-4D98-83AC-3BD0EBFEE5C4

Q37100862-4AAE35E6-3D7F-4CC3-8674-17B075DFC5B3

Q37100862-53A88079-C155-46C2-8FE3-A14C010E21E3

Q37100862-60FC323F-9698-4C9C-944E-9B4646918F92

Q37100862-784895B0-1F31-403E-9557-839D2236AB4A

Q37100862-B01C7154-F49D-4143-8378-793E577074CA

Q37100862-B77C5511-BDB4-4B93-9017-D128E65CA6D1

Q37100862-C287B573-F64F-42F7-8192-33323BEB297A

P2860

Q37100862-0037A011-876E-41FC-9872-4F5EB894C0F4

Q37100862-003AEF1C-669C-447B-ADE6-AFC40DF4C131

Q37100862-08CFE12B-46F6-4B21-82CE-B33A3E85CE82

Q37100862-1931CFAB-9BA7-4859-9D80-2BD609FF7AC4

Q37100862-338B8A75-A890-42CA-9A93-DE6E002446D6

Q37100862-3A68D170-8927-42C0-A7BD-032E1B8DE145

Q37100862-459C476D-98A3-48E5-A902-89C3F30478C3

Q37100862-565BD5C7-3FAD-4DE8-BCD3-AAF166B03154

Q37100862-714E582A-3D39-4880-8FE8-72D669F3B4B3

Q37100862-7E26F556-29E3-4806-84BF-B867586EEC78

P304

Q37100862-8A527B33-50C9-4AC8-AA6B-2C2EBFE10469

P31

Q37100862-C22C0005-39D0-4492-BAF0-4ECF6644E0C3

P356

Q37100862-FE0AC81D-8940-41A3-AF1B-64BE2236C897

P433

Q37100862-1704C532-4245-45BB-8E3F-06D9EC89C65E

P478

Q37100862-3E2D7A89-EC8B-4162-BCEE-1A4AD1A4C7E1

P577

Q37100862-5AEFE53D-100D-44ED-92D7-D76943BDED1F

P698

Q37100862-8A947E5E-80A4-4AA0-906B-FDDC08771B2F

P921

Q37100862-42D28D49-1682-4BB8-9CFE-AB410C6B195C

Q37100862-A77FD0E1-13CD-4F81-8BCE-6DC5A59C4536

P932

Q37100862-BD9EB96C-0CB6-48C7-8EC5-048755DB6778

P356

J.JCMG.2012.11.017

P1433

JACC: Cardiovascular Imaging

P1476

Low to moderate dose anthracyc ...... inical cardiovascular disease.

@en

P2093

Brandon C Drafts

http://www.w3.org/2001/XMLSchema#string

Craig A Hamilton

http://www.w3.org/2001/XMLSchema#string

Frank M Torti

http://www.w3.org/2001/XMLSchema#string

Jennifer Jordan

http://www.w3.org/2001/XMLSchema#string

Julia Lawrence

http://www.w3.org/2001/XMLSchema#string

Katie M Twomley

http://www.w3.org/2001/XMLSchema#string

Leslie R Ellis

http://www.w3.org/2001/XMLSchema#string

Nancy Avis

http://www.w3.org/2001/XMLSchema#string

Ralph D'Agostino

http://www.w3.org/2001/XMLSchema#string

Susan A Melin

http://www.w3.org/2001/XMLSchema#string

P2860

2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration

Outcome of heart failure with preserved ejection fraction in a population-based study

Cardiovascular disease risk factors: epidemiology and risk assessment.

Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy.

Myocardial tissue tagging with cardiovascular magnetic resonance.

Traditional cardiovascular risk factors in relation to left ventricular mass, volume, and systolic function by cardiac magnetic resonance imaging: the Multiethnic Study of Atherosclerosis.

Telmisartan, ramipril, or both in patients at high risk for vascular events.

Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy.

Aortic stiffness increases upon receipt of anthracycline chemotherapy

Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients.

P304

877-885

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JCMG.2012.11.017

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23643285

http://www.w3.org/2001/XMLSchema#string

P921

cardiovascular disease

P932

3745801

http://www.w3.org/2001/XMLSchema#string